| Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer F André, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ... New England Journal of Medicine 380 (20), 1929-1940, 2019 | 1997 | 2019 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 1214 | 2020 |
| Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: Final overall survival … F André, EM Ciruelos, D Juric, S Loibl, M Campone, IA Mayer, ... Annals of Oncology 32 (2), 208-217, 2021 | 361 | 2021 |
| Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla–surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast … Á Sávolt, G Péley, C Polgár, N Udvarhelyi, G Rubovszky, E Kovács, ... European Journal of Surgical Oncology (EJSO) 43 (4), 672-679, 2017 | 263 | 2017 |
| Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study EL Mayer, AC Dueck, M Martin, G Rubovszky, HJ Burstein, ... The lancet oncology 22 (2), 212-222, 2021 | 225 | 2021 |
| Alpelisib (ALP)+ fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial F André, EM Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ... Annals of Oncology 29, viii709, 2018 | 99 | 2018 |
| Abstract GS3-08: Alpelisib+ fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial D Juric, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, H Iwata, ... Cancer research 79 (4_Supplement), GS3-08-GS3-08, 2019 | 77 | 2019 |
| Recent advances in the neoadjuvant treatment of breast cancer G Rubovszky, Z Horváth Journal of Breast Cancer 20 (2), 119, 2017 | 75 | 2017 |
| Cetuximab and platinum-based chemoradio-or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial E Hitre, B Budai, Z Takacsi-Nagy, G Rubovszky, E Toth, E Remenar, ... British journal of cancer 109 (5), 1117-1122, 2013 | 69 | 2013 |
| Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study G Rubovszky, I Láng, E Ganofszky, Z Horváth, E Juhos, T Nagy, E Szabó, ... European Journal of Cancer 49 (18), 3806-3812, 2013 | 55 | 2013 |
| LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP)+ fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor … F André, EM Ciruelos, D Juric, S Loibl, M Campone, I Mayer, ... Annals of Oncology 31, S1150-S1151, 2020 | 39 | 2020 |
| LBA12 Pallas: a randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2-early breast cancer EL Mayer, MI Gnant, A DeMichele, M Martin, H Burstein, A Prat, ... Annals of Oncology 31, S1145, 2020 | 39 | 2020 |
| Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial Á Sávolt, P Musonda, Z Mátrai, C Polgár, F Rényi-Vámos, G Rubovszky, ... Orvosi hetilap 154 (49), 1934-1942, 2013 | 35 | 2013 |
| Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial TA Yap, A Bardia, M Dvorkin, MD Galsky, JT Beck, DR Wise, O Karyakin, ... JAMA oncology 9 (1), 40-50, 2023 | 29 | 2023 |
| Management strategies for hyperglycemia associated with the α-selective PI3K inhibitor alpelisib for the treatment of breast cancer T Tankova, E Senkus, M Beloyartseva, S Borštnar, D Catrinoiu, M Frolova, ... Cancers 14 (7), 1598, 2022 | 20 | 2022 |
| Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: results from advanced breast cancer cohorts TA Yap, P Konstantinopoulos, ML Telli, S Saraykar, JT Beck, MD Galsky, ... Cancer Research 80 (4_Supplement), P1-19-03-P1-19-03, 2020 | 18 | 2020 |
| A long-term retrospective comparative study of the oncological outcomes of 598 very young (≤ 35 years) and young (36–45 years) breast cancer patients A Szollár, M Újhelyi, C Polgár, E Oláh, D Pukancsik, G Rubovszky, ... European Journal of Surgical Oncology 45 (11), 2009-2015, 2019 | 18 | 2019 |
| Systemic treatment of breast cancer. 1st central-eastern European professional consensus statement on breast cancer G Rubovszky, J Kocsis, K Boér, N Chilingirova, M Dank, Z Kahán, ... Pathology and Oncology Research 28, 1610383, 2022 | 16 | 2022 |
| Alpelisib (ALP)+ fulvestrant (FUL) for advanced breast cancer (ABC): Phase 3 SOLAR-1 trial results D Juric, EM Ciruelos, G Rubovszky, M Campone, S Loibl, H Rugo, ... San Antonio Breast Cancer Symposium 4 (8), 2018 | 16 | 2018 |
| Pancreatic cancer. Evidence based management guidelines of the Hungarian Pancreatic Study Group R Szmola, G Farkas, P Hegyi, L Czakó, Z Dubravcsik, I Hritz, D Kelemen, ... Orvosi hetilap 156 (8), 326-339, 2015 | 14 | 2015 |
Hope RugoProfessor of Medicine, University of California San FranciscoVerified email at ucsf.edu
